Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was combined with PD1 checkpoint inhibition in a murine model of ovarian cancer.
Lead Product(s): Allocetra,Undisclosed
Therapeutic Area: Oncology Product Name: Allocetra
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Enlivex Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2022